Nanoglia

Nanoglia is a South Korean biotechnology company specializing in the research and development of innovative therapeutics using nanotechnology. Founded in 2019 as a spin-off from Chungnam National University, the company utilizes its proprietary poly(lactic-co-glycolic acid) (PLGA) nanoparticle platform to deliver gene regulators, such as small interfering RNAs (siRNAs) and plasmids, directly to target cells. Nanoglia's pipeline focuses on treating neuroinflammatory and neurodegenerative diseases, neuropathic pain, osteoarthritis, and allergic rhinitis by targeting glial-neuronal interactions and microglial activation. In addition to its therapeutic pipeline, the company offers custom nanoparticle synthesis, tracking, and analysis services to support academic and industrial research.